In recent years, the use of tumor necrosis factor inhibitors (TNFi) has resulted in an improvement in the treatment of RA patients by reducing both inflammation and joint damage [2-4], and their clinical use has become widespread. This evidence concerns the gene TNF and rheumatoid arthritis.